ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PTHS vs CSBR // NET PROFIT MARGIN

Pelthos Therapeutics Inc. (NYSE) VS. Champions Oncology Inc. (NASDAQ) • 15-METRIC TALLY: PTHS 2 — CSBR 5
▲ NET PROFIT MARGIN LEADER: CSBR
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTHS VS. CSBR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PTHS CSBR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 76.30% 48.00% +28.30 PTHS /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -26.90% -8.10 CSBR /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -7.52% — TIE /fcf-yield <GO>
Operating Margin -60.00% -1.90% -58.10 CSBR /operating-margins <GO>
Net Profit Margin ACTIVE -60.00% 0.00% -60.00 CSBR /net-margins <GO>
Revenue Growth (YoY) — 4.40% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 0.20 0.00 TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 PTHS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 21.8 46.7 -24.87 CSBR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $63.3M $66.9M -$3.6M CSBR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PTHS REV CSBR REV PTHS GROSS % CSBR GROSS % PTHS FCF CSBR FCF
FY 2025 $16.8M $59.4M 76.3% 48.0% -$22.7M -$5.0M
FY 2024 $0 $56.9M — 50.1% -$5.8M $7.0M
FY 2023 $0 $50.2M — — -$981.0K -$6.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTHS // BETA —
CSBR // BETA —